Results 61 to 70 of about 20,740 (205)

Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oxidative stress is involved in several key processes in cancer, including redox regulation, DNA damage, post‐translational modifications, transcriptional regulation, epigenetic modifications, metabolic reprogramming, cell death, and immune modulation. These mechanisms collectively influence tumor progression, immune evasion, and therapeutic responses,
Zhen Wang, Bowen Li, Pan Tang, Fanchen Yan, Shuxin Wang, Guiying Leng, Panduo Dawa, Yuansi Chen, Yihan Guo, Pan Yang, Yi Li, Siyu Liu, Erdan Dong, Siyuan Qin, Zhoufeng Wang   +14 more
wiley   +1 more source

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. [PDF]

, 1995
To determine the functional importance of Ras in transformation by Abl oncogenes, we used a genetic approach to measure the effect of impaired Ras activity on the ability of Bcr-Abl or v-Abl to transform cells.
McLaughlin, J, Sawyers, CL, Witte, ON
core  

BCR–ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ

MedComm, Volume 7, Issue 5, May 2026.
There is global immunosuppression during CML initiation and progression, which is directly driven by BCR–ABL1 expressing CML cells. On one hand, the BCR–ABL1 oncogene drives the differentiation of leukemia cells toward the neutrophil lineage. On the other hand, the oncogene also transcriptionally activates master immune regulators, including arginase ...
Xiaocui Lu, Hui Fang, Yuan Liu, Chang Liu, Xuexiu Fang, Atsuko Matsunaga, Stephanie F. Mori, Ting Zhang, Gavin Wang, George I. Zhou, Miao Yu, Haocheng Ding, Jorge Cortes, Bo Cheng, Tianxiang Hu   +14 more
wiley   +1 more source

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins [PDF]

Blood, 1997
CGP 57148 is a compound of the 2-phenylaminopyrimidine class that selectively inhibits the tyrosine kinase activity of the ABL and the platelet-derived growth factor receptor (PDGFR) protein tyrosine kinases. We previously showed that CGP 57148 selectively kills p210BCR-ABL–expressing cells. To extend these observations, we evaluated the ability of CGP
M, Carroll, S, Ohno-Jones, S, Tamura, E, Buchdunger, J, Zimmermann, N B, Lydon, D G, Gilliland, B J, Druker   +7 more
openaire   +3 more sources

Direct genetic demonstration of Gα13 coupling to the orphan G protein-coupled receptor G2A leading to RhoA-dependent actin rearrangement [PDF]

, 2000
G2A is an orphan G protein-coupled receptor (GPCR), expressed predominantly in T and B cells and homologous to a small group of GPCRs of unknown function expressed in lymphoid tissues.
Feramisco, Jamison D., Gu, Jennifer L., Kabarowski, Janusz H. S., Le, Lu Q., Luoh, Shiuh-Wen, Simon, Melvin I., Witte, Owen N.   +6 more
core  

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules [PDF]

Leukemia, 2000
The Philadelphia (Ph) chromosome, resulting from the t(9;22) translocation, is characteristic of chronic myeloid leukemia (CML). As a result of this translocation, two novel chimeric genes are generated and the bcr/abl and abl/bcr fusion proteins expressed.
Berke, Z., Andersen, M.H., Pedersen, M., Fugger, L., Zeuthen, J.and, Haurum, J.S.   +5 more
openaire   +3 more sources

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor β gene

Haematologica, 2007
Background and Objectives We sought to identify new fusion genes with involvement of the platelet-derived growth factor receptor β gene (PDGFRB) in three patients presenting with various subtypes of chronic myeloproliferative disorders associated with ...
Christoph Walz, Georgia Metzgeroth, Claudia Haferlach, Annette Schmitt-Graeff, Alice Fabarius, Volker Hagen, Otto Prümmer, Stefan Rauh, Rüdiger Hehlmann, Andreas Hochhaus, Nicholas C.P. Cross, Andreas Reiter   +11 more
doaj   +1 more source

Biology-driven cancer drug development: back to the future [PDF]

, 2010
Most of the significant recent advances in cancer treatment have been based on the great strides that have been made in our understanding of the underlying biology of the disease.
Christopher J Lord, Alan Ashworth, K Strebhardt, J Hirsch, L Goodman, S Farber, G Hitchings, IS Johnson, E Frei, MP Cole, J Bennett, CG Geary, P Nowell, JD Rowley, HT Abelson, SP Goff, A de Klein, J Groffen, E Shtivelman, BM Sefton, JB Konopka, N Heisterkamp, GQ Daley, JV Melo, P Yaish, H Piwnica-Worms, BJ Druker, BJ Druker, ME Gorre, AS Corbin, T Schindler, E Weisberg, LJ Lombardo, J Zhang, MA Siddiqui, JF Apperley, J Zhang, J Baselga, DD Von Hoff, CM Rudin, C Nusslein-Volhard, J Jiang, V Gray-Schopfer, N Dhomen, P Chapman, SJ Heidorn, D Hanahan, J Luo, G Kroemer, JH Hoeijmakers, RI Morimoto, AJ Holland, O Warburg, CC Benz, HR Christofk, H Farmer, WG Kaelin Jr, PC Fong, IB Weinstein, E Iorns, C Scholl, J Luo, DA Barbie, Y Wang, R Firestein, JS Boehm, CK Hahn, PJ Campbell, SP Shah, ED Pleasance, ED Pleasance, PJ Stephens, CM Perou, NM Griffin, JK Nicholson, SL Edwards, MW Deininger, BJ Druker   +77 more
core   +1 more source

Radioiodination of Two Carborane‐Based Dual Cyclooxygenase‐2/5‐Lipoxygenase Inhibitors and Their In Vitro and In Vivo Evaluation

ChemBioChem, Volume 27, Issue 7, 14 April 2026.
Two dicarbadodecaborane(12)‐based dual cyclooxygenase‐2/5‐lipoxygenase (COX‐2/5‐LO) inhibitors were 123I‐labeled. Refinement of labeling and formulation conditions and extensive in vitro characterization are presented. Cell uptake studies in COX‐2‐ and 5‐LO‐overexpressing cell lines showed COX‐2‐independent and partly 5‐LO‐dependent uptake.
Jonas Schädlich, Martin Ullrich, Cathleen Haase‐Kohn, Robert Wodtke, Sebastian Braun, Maximilian Molitor, Bettina Hofmann, Dieter Steinhilber, Klaus Kopka, Evamarie Hey‐Hawkins, Jens Pietzsch, Markus Laube   +11 more
wiley   +1 more source

Differential Signaling through p190 and p210 Forms of BCR-ABL Fusion Proteins Revealed By Proteomic Analysis

Blood, 2015
Abstract Chromosomal translocations involving chromosome 9q34 and 22q11 generate the BCR-ABL1 fusion gene. The location of the translocation within the BCR gene dictates which exons are excluded or included in the resulting fusion with the ABL1 gene.
Jevon Cutler, Rahia Tahir, Jingnan Han, Raja Sekhar Nirujogi, Tai-Chung Huang, Xianrong Wong, Saradhi Mallampati, Xiaoping Sun, Patrick Brown, Karen Reddy, Akhilesh Pandey   +10 more
openaire   +1 more source